1
|
Zhang Z, Zhou J, Guo R, Zhou Q, Wang L, Xiang X, Ge S, Cui Z. Network pharmacology to explore the molecular mechanisms of Prunella vulgaris for treating thyroid cancer. Medicine (Baltimore) 2023; 102:e34871. [PMID: 37960775 PMCID: PMC10637567 DOI: 10.1097/md.0000000000034871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Accepted: 08/01/2023] [Indexed: 11/15/2023] Open
Abstract
BACKGROUND Thyroid cancer (TC) is the most common endocrine malignancy that has rapidly increased in global incidence. Prunella vulgaris (PV) has manifested therapeutic effects in patients with TC. We aimed to investigate its molecular mechanisms against TC and provide potential drug targets by using network pharmacology and molecular docking. METHODS The ingredients of PV were retrieved from Traditional Chinese Medicine Systematic Pharmacology Database. TC-related gene sets were established using the GeneCard and OMIM databases. The establishment of the TC-PV target gene interaction network was accomplished using the STRING database. Cytoscape constructed networks for visualization. Protein-protein interaction, gene ontology and the biological pathway Kyoto encyclopedia of genes and genomes enrichment analyses were performed to discover the potential mechanism. Molecular docking technology was used to analyze the effective compounds from PV for treating TC. RESULTS 11 active compounds and 192 target genes were screened from PV. 177 potential targets were obtained by intersecting PV and TC gene sets. Network pharmacological analysis showed that the PV active ingredients including Vulgaxanthin-I, quercetin, Morin, Stigmasterol, poriferasterol monoglucoside, Spinasterol, kaempferol, delphinidin, stigmast-7-enol, beta-sitosterol and luteolin showed better correlation with TC target genes such as JUN, AKT1, mitogen-activated protein kinase 1, IL-6 and RELA. The gene ontology and Kyoto encyclopedia of genes and genomes indicated that PV can act by regulating the host defense and response to oxidative stress immune response and several signaling pathways are closely associated with TC, such as the TNF and IL-17. Protein-protein interaction network identified 8 hub genes. The molecular docking was conducted on the most significant gene MYC. Eleven active compounds of PV can enter the active pocket of MYC, namely poriferasterol monoglucoside, stigmasterol, beta-sitosterol, vulgaxanthin-I, spinasterol, stigmast-7-enol, luteolin, delphinidin, morin, quercetin and kaempferol. Further analysis showed that oriferasterol monoglucoside, followed by tigmasterol, were the potential therapeutic compound identified in PV for the treatment of TC. CONCLUSION The network pharmacological strategy integrates molecular docking to unravel the molecular mechanism of PV. MYC is a promising drug target to reduce oxidative stress damage and potential anti-tumor effect. Oriferasterol monoglucoside and kaempferol were 2 bioactive compounds of PV to treat TC. This provides a basis to understand the mechanism of the anti-TC activity of PV.
Collapse
Affiliation(s)
- Zhiqiang Zhang
- Otolaryngology Head and Neck Surgery Institute, The Affiliated Hospital of Yanbian University, Yanbian University, Jilin, China
| | - Jiayi Zhou
- Oncology Institute, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar Medical University, Heilongjiang, China
| | - Ruiqian Guo
- Oncology Institute, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar Medical University, Heilongjiang, China
| | - Qijun Zhou
- Basic Medical College of Qiqihar Medical University, Qiqihar Medical University, Heilongjiang, China
| | - Lianzhi Wang
- Basic Medical College of Qiqihar Medical University, Qiqihar Medical University, Heilongjiang, China
| | - Xingyan Xiang
- Oncology Institute, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar Medical University, Heilongjiang, China
| | - Sitong Ge
- Otolaryngology Head and Neck Surgery Institute, The Affiliated Hospital of Yanbian University, Yanbian University, Jilin, China
| | - Zhezhu Cui
- Otolaryngology Head and Neck Surgery Institute, The Affiliated Hospital of Yanbian University, Yanbian University, Jilin, China
| |
Collapse
|
2
|
Singla RK, De R, Efferth T, Mezzetti B, Sahab Uddin M, Ntie-Kang F, Wang D, Schultz F, Kharat KR, Devkota HP, Battino M, Sur D, Lordan R, Patnaik SS, Tsagkaris C, Sai CS, Tripathi SK, Găman MA, Ahmed MEO, González-Burgos E, Babiaka SB, Paswan SK, Odimegwu JI, Akram F, Simal-Gandara J, Urquiza MS, Tikhonov A, Mondal H, Singla S, Lonardo SD, Mulholland EJ, Cenanovic M, Maigoro AY, Giampieri F, Lee S, Tzvetkov NT, Louka AM, Verma P, Chopra H, Olea SP, Khan J, Alvarez Suarez JM, Zheng X, Tomczyk M, Sabnani MK, Medina CDV, Khalid GM, Boyina HK, Georgiev MI, Supuran CT, Sobarzo-Sánchez E, Fan TP, Pittala V, Sureda A, Braidy N, Russo GL, Vacca RA, Banach M, Lizard G, Zarrouk A, Hammami S, Orhan IE, Aggarwal BB, Perry G, Miller MJ, Heinrich M, Bishayee A, Kijjoa A, Arkells N, Bredt D, Wink M, Fiebich BL, Kiran G, Yeung AWK, Gupta GK, Santini A, Lucarini M, Durazzo A, El-Demerdash A, Dinkova-Kostova AT, Cifuentes A, Souto EB, Zubair MAM, Badhe P, Echeverría J, Horbańczuk JO, Horbanczuk OK, Sheridan H, Sheshe SM, Witkowska AM, Abu-Reidah IM, Riaz M, Ullah H, Oladipupo AR, Lopez V, Sethiya NK, Shrestha BG, Ravanan P, Gupta SC, Alzahrani QE, Dama Sreedhar P, Xiao J, Moosavi MA, Subramani PA, Singh AK, Chettupalli AK, Patra JK, Singh G, Karpiński TM, Al-Rimawi F, Abiri R, Ahmed AF, Barreca D, Vats S, Amrani S, Fimognari C, Mocan A, Hritcu L, Semwal P, Shiblur Rahaman M, Emerald M, Akinrinde AS, Singh A, Joshi A, Joshi T, Khan SY, Balla GOA, Lu A, Pai SR, Ghzaiel I, Acar N, Es-Safi NE, Zengin G, Kureshi AA, Sharma AK, Baral B, Rani N, Jeandet P, Gulati M, Kapoor B, Mohanta YK, Emam-Djomeh Z, Onuku R, Depew JR, Atrooz OM, Goh BH, Andrade JC, Konwar B, Shine VJ, Ferreira JMLD, Ahmad J, Chaturvedi VK, Skalicka-Woźniak K, Sharma R, Gautam RK, Granica S, Parisi S, Kumar R, Atanasov AG, Shen B. The International Natural Product Sciences Taskforce (INPST) and the power of Twitter networking exemplified through #INPST hashtag analysis. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2023; 108:154520. [PMID: 36334386 DOI: 10.1016/j.phymed.2022.154520] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Revised: 07/12/2022] [Accepted: 10/21/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND The development of digital technologies and the evolution of open innovation approaches have enabled the creation of diverse virtual organizations and enterprises coordinating their activities primarily online. The open innovation platform titled "International Natural Product Sciences Taskforce" (INPST) was established in 2018, to bring together in collaborative environment individuals and organizations interested in natural product scientific research, and to empower their interactions by using digital communication tools. METHODS In this work, we present a general overview of INPST activities and showcase the specific use of Twitter as a powerful networking tool that was used to host a one-week "2021 INPST Twitter Networking Event" (spanning from 31st May 2021 to 6th June 2021) based on the application of the Twitter hashtag #INPST. RESULTS AND CONCLUSION The use of this hashtag during the networking event period was analyzed with Symplur Signals (https://www.symplur.com/), revealing a total of 6,036 tweets, shared by 686 users, which generated a total of 65,004,773 impressions (views of the respective tweets). This networking event's achieved high visibility and participation rate showcases a convincing example of how this social media platform can be used as a highly effective tool to host virtual Twitter-based international biomedical research events.
Collapse
Affiliation(s)
- Rajeev K Singla
- Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Xinchuan Road 2222, Chengdu, Sichuan, China; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab-144411, India
| | - Ronita De
- ICMR-National Institute of Cholera and Enteric Diseases, P-33, CIT Rd, Subhas Sarobar Park, Phool Bagan, Beleghata, Kolkata, West Bengal 700010, India
| | - Thomas Efferth
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Bruno Mezzetti
- Department of Agriculture, Food and Environmental Sciences (D3A) Università Politecnica Delle Marche Ancona, IT, Italy
| | - Md Sahab Uddin
- Department of Pharmacy, Southeast University, Dhaka, Bangladesh; Pharmakon Neuroscience Research Network, Dhaka, Bangladesh
| | - Fidele Ntie-Kang
- Department of Chemistry, Faculty of Science, University of Buea, Buea P.O. Box 63, Cameroon
| | - Dongdong Wang
- Centre for Metabolism, Obesity, and Diabetes Research, Department of Medicine, McMaster University, HSC 4N71, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada
| | - Fabien Schultz
- Technical University of Berlin, Institute of Biotechnology, Faculty III - Process Sciences, Gustav-Meyer-Allee 25, Berlin 13355, Germany; Neubrandenburg University of Applied Sciences, Department of Agriculture and Food Sciences, Brodaer Str. 2, Neubrandenburg 17033, Germany
| | | | - Hari Prasad Devkota
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1Oe-honmachi, Kumamoto 862-0973, Japan; Program for Leading Graduate Schools, HIGO Program, Kumamoto University, Japan
| | - Maurizio Battino
- Department of Clinical Sciences, Faculty of Medicine, Polytechnic University of Marche, Ancona 60131, Italy; International Research Center for Food Nutrition and Safety, Jiangsu University, Zhenjiang 212013, China
| | - Daniel Sur
- Department of Medical Oncology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Romania
| | - Ronan Lordan
- Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, PA, United States
| | - Sourav S Patnaik
- Department of Bioengineering, University of Texas at Dallas, Richardson, TX, United States
| | | | - Chandragiri Siva Sai
- Amity Institute of Pharmacy, Amity University, Uttar Pradesh, Lucknow Campus, Gomati Nagar, Lucknow, Uttar Pradesh 226010, India
| | - Surya Kant Tripathi
- Cancer Drug Resistance Laboratory, National Institute of Technology Rourkela, Odisha-769008, India
| | - Mihnea-Alexandru Găman
- ″Carol Davila" University of Medicine and Pharmacy, 8 Eroii Sanitari Boulevard, Bucharest, Romania; Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, 258 Fundeni Road, Bucharest, Romania
| | - Mosa E O Ahmed
- Department of Pharmacognosy, Faculty of Pharmacy, Al Neelain University, Khartoum, Sudan
| | - Elena González-Burgos
- Department of Pharmacology, Pharmacognosy and Botany, University Complutense of Madrid, Spain
| | - Smith B Babiaka
- Department of Chemistry, Faculty of Science, University of Buea, Buea P.O. Box 63, Cameroon
| | | | | | - Faizan Akram
- Bahawalpur College of Pharmacy (BCP), Bahawalpur Medical and Dental College (BMDC), Bahawalpur, Pakistan
| | - Jesus Simal-Gandara
- Universidade de Vigo, Nutrition and Bromatology Group, Department of Analytical Chemistry and Food Science, Faculty of Science, Ourense E-32004, Spain
| | | | - Aleksei Tikhonov
- Translational Research Laboratory in Immunotherapy, Gustave Roussy, Villejuif, France
| | - Himel Mondal
- Department of Physiology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India
| | - Shailja Singla
- iGlobal Research and Publishing Foundation, New Delhi, India
| | - Sara Di Lonardo
- Research Institute on Terrestrial Ecosystems-Italian National Research Council (IRET-CNR), Via Madonna del Piano 10, Sesto Fiorentino Fi 50019, Italy
| | - Eoghan J Mulholland
- Gastrointestinal Stem Cell Biology Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom; Somerville College, University of Oxford, Oxford, United Kingdom
| | | | | | - Francesca Giampieri
- Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia; Research Group on Food, Nutritional Biochemistry and Health, Universidad Europea del Atlántico, Santander, Spain
| | - Soojin Lee
- Department of Bioscience and Biotechnology, Chungnam National University, Republic of Korea
| | - Nikolay T Tzvetkov
- Department of Biochemical Pharmacology and Drug Design, Institute of Molecular Biology "Roumen Tsanev", Bulgarian Academy of Sciences, Bulgaria
| | | | - Pritt Verma
- Department of Pharmacology, CSIR-NBRI, Lucknow, India
| | - Hitesh Chopra
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| | | | - Johra Khan
- Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Al Majmaah 11952, Saudi Arabia
| | - José M Alvarez Suarez
- Departamento de Ingeniería en Alimentos, Colegio de Ciencias e Ingenierías, Universidad San Francisco de Quito, Quito, Ecuador
| | - Xiaonan Zheng
- Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Michał Tomczyk
- Department of Pharmacognosy, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, ul. Mickiewicza 2a, Białystok 15-230, Poland
| | - Manoj Kumar Sabnani
- The University of Texas at Arlington, United States; Alloy Therapeutics, United States
| | | | - Garba M Khalid
- Pharmaceutical Engineering Group, School of Pharmacy, Queen's University, Belfast BT9, United Kingdom
| | - Hemanth Kumar Boyina
- School of Pharmacy, Department of Pharmacology, Anurag University, Venkatapur, Medchal, Hyderabad, Telangana 500088, India
| | - Milen I Georgiev
- Laboratory of Metabolomics, Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 139 Ruski Blvd., Plovdiv 4000, Bulgaria
| | | | - Eduardo Sobarzo-Sánchez
- Instituto de Investigación y Postgrado, Facultad de Ciencias de la Salud, Universidad Central de Chile, Santiago 8330507, Chile; Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Tai-Ping Fan
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Faculty of Life Science and Medicine, Northwest University, Xi'an, China
| | - Valeria Pittala
- Department of Drug and Health Sciences, University of Catania, Catania, Italy
| | - Antoni Sureda
- Research Group in Community Nutrition and Oxidative Stress, University of the Balearic Islands-IUNICS, Health Research Institute of Balearic Islands (IdISBa), and CIBEROBN (Physiopathology of Obesity and Nutrition), Palma, Balearic Islands E-07122, Spain
| | - Nady Braidy
- Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia
| | - Gian Luigi Russo
- National Research Council, Institute of Food Sciences, Avellino 83100, Italy
| | - Rosa Anna Vacca
- Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Council of Research, Bari 70126, Italy
| | - Maciej Banach
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland
| | - Gérard Lizard
- Université de Bourgogne / Inserm, Laboratoire Bio-PeroxIL, Faculté des Sciences Gabriel, 6 Boulevard Gabriel, Dijon 21000 France
| | - Amira Zarrouk
- University of Monastir (Tunisia), Faculty of Medicine, LR-NAFS 'Nutrition - Functional Food & Vascular Health', Tunisia
| | - Sonia Hammami
- University of Monastir (Tunisia), Faculty of Medicine, LR-NAFS 'Nutrition - Functional Food & Vascular Health', Tunisia
| | - Ilkay Erdogan Orhan
- Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Ankara 06330, Türkiye
| | | | - George Perry
- Department of Neuroscience, Developmental, and Regenerative Biology, University of Texas, United States
| | | | | | - Anupam Bishayee
- College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, United States
| | - Anake Kijjoa
- Instituto de Ciências Biomédicas Abel Salazar e CIIMAR, Universidade do Porto, Portugal
| | - Nicolas Arkells
- International Natural Product Sciences Taskforce (INSPT), United States
| | | | - Michael Wink
- Heidelberg University, Institute of Pharmacy and Molecular Biotechnology (IPMB), Heidelberg 69120, Germany
| | - Bernd L Fiebich
- Neurochemistry and Neuroimmunology Research Group, Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | | | - Andy Wai Kan Yeung
- Oral and Maxillofacial Radiology, Applied Oral Sciences and Community Dental Care, Faculty of Dentistry, University of Hong Kong, Hong Kong, China
| | - Girish Kumar Gupta
- Department of Pharmaceutical Chemistry, Sri Sai College of Pharmacy, Badhani, Pathankot, Punjab, India
| | - Antonello Santini
- University of Napoli Federico II, Department of Pharmacy. Via D Montesano 49, Napoli 80131, Italy
| | - Massimo Lucarini
- CREA-Research Centre for Food and Nutrition, Via Ardeatina 546 00178 Rome, Italy
| | - Alessandra Durazzo
- CREA-Research Centre for Food and Nutrition, Via Ardeatina 546 00178 Rome, Italy
| | - Amr El-Demerdash
- Metabolic Biology & Biological Chemistry Department, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, United Kingdom; Organic Chemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura 35516, Egypt
| | | | | | - Eliana B Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, Porto 4050-313, Portugal
| | | | - Pravin Badhe
- Swalife Foundation, India; Swalife Biotech Ltd, Ireland; Sinhgad College of Pharmacy, Vadgaon (BK) Pune Maharashtra India
| | - Javier Echeverría
- Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Chile
| | - Jarosław Olav Horbańczuk
- Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzębiec 05-552, Poland
| | - Olaf K Horbanczuk
- Department of Technique and Food Product Development, Warsaw University of Life Sciences (WULS-SGGW) 159c Nowoursynowska, Warsaw 02-776, Poland
| | - Helen Sheridan
- The NatPro Centre. Trinity College Dublin. Dublin 2, Ireland
| | | | | | - Ibrahim M Abu-Reidah
- School of Science and the Environment, Grenfell Campus, Memorial University of Newfoundland, Corner Brook A2H 5G4, Canada
| | - Muhammad Riaz
- Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal 18050, Pakistan
| | - Hammad Ullah
- Department of Pharmacy, University of Naples Federico II, Naples 80131, Italy
| | - Akolade R Oladipupo
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Lagos, Nigeria; Department of Chemistry, Nelson Mandela University, Port Elizabeth, South Africa
| | - Víctor Lopez
- Department of Pharmacy, Universidad San Jorge, Villanueva de Gállego (Zaragoza), Spain
| | | | | | - Palaniyandi Ravanan
- Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Thiruvarur, India
| | - Subash Chandra Gupta
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, India; Department of Biochemistry, All India Institute of Medical Sciences, Guwahati, Assam, India
| | - Qushmua E Alzahrani
- Department of Pharmacy/Nursing Medicine Health and Environment, University of the Region of Joinville (UNIVILLE) Brazil, Sana Catarina, Joinville, Brazil
| | | | | | - Mohammad Amin Moosavi
- Molecular Medicine Department, Institute of Medical Biotechnology, National Institute of Genetics Engineering and Biotechnology, Tehran P.O. Box: 14965/161, Iran
| | - Parasuraman Aiya Subramani
- Independent Researcher, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Chennai, India - 600048. formerly, Pallavaram, Chennai 600117, India
| | - Amit Kumar Singh
- Department of Biochemistry, University of Allahabad, Prayagraj 211002 India
| | | | - Jayanta Kumar Patra
- Research Institute of Integrative Life Sciences, Dongguk University-Seoul, Goyangsi 10326, Republic of Korea
| | - Gopal Singh
- Department of Plant Functional Metabolomics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
| | - Tomasz M Karpiński
- Chair and Department of Medical Microbiology, Poznań University of Medical Sciences, Wieniawskiego 3, Poznań 61-712, Poland
| | | | - Rambod Abiri
- Department of Forestry Science and Biodiversity, Faculty of Forestry and Environment, Universiti Putra Malaysia, UPM Serdang, Selangor 43400, Malaysia
| | - Atallah F Ahmed
- Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
| | - Davide Barreca
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Università degli Studi di Messina, Messina, Italy
| | - Sharad Vats
- Department of Bioscience and Biotechnology, Banasthali Vidyapith, Rajasthan 304022, India
| | - Said Amrani
- Laboratoire de Biologie et de Physiologie des Organismes, Faculté des Sciences Biologiques, USTHB, Bab Ezzouar, Alger, Algeria
| | | | - Andrei Mocan
- Department of Pharmaceutical Botany, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Lucian Hritcu
- Department of Biology, Alexandru Ioan Cuza University of Iasi, Bd. Carol I, No. 11, Iasi 700506, Romania
| | - Prabhakar Semwal
- Department of Life Sciences, Graphic Era Deemed to be University, Dehradun, Uttarakhand 248002, India
| | - Md Shiblur Rahaman
- Department of Environmental and Preventive Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
| | - Mila Emerald
- PHYTOCEUTICALS International™ & NOVOTEK Global Solutions™, Canada
| | - Akinleye Stephen Akinrinde
- Department of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria
| | | | - Ashima Joshi
- Sardar Bhagwan Singh University, Balawala, Dehradun, India
| | - Tanuj Joshi
- Department of Pharmaceutical Sciences, Bhimtal, Kumaun University (Nainital), India
| | - Shafaat Yar Khan
- Research Lab III, Hematology & Vascular Biology, Department of Zoology, University of Sargodha, Sargodha, Pakistan
| | - Gareeballah Osman Adam Balla
- Department of Pharmacology, College of Veterinary Medicine, Sudan University of Science and Technology, Hilat Kuku, Khartoum North P.O. Box No. 204, Sudan
| | - Aiping Lu
- School of Chinese Medicine, Hong Kong Baptist University, HongKong, China
| | - Sandeep Ramchandra Pai
- Department of Botany, Rayat Shikshan Sanstha's, Dada Patil Mahavidyalaya, Karjat, Maharashtra, India
| | - Imen Ghzaiel
- Université de Bourgogne, Inserm, Laboratoire Bio - PeroxIL, Faculté des Sciences Gabriel, 6 Boulevard Gabriel, Dijon 21000 France; University Tunis El Manar, Tunis, Tunisia
| | | | - Nour Eddine Es-Safi
- Mohammed V University in Rabat, LPCMIO, Materials Science Center (MSC), Ecole Normale Supérieure, Rabat, Morocco
| | - Gokhan Zengin
- Department of Biology, Science Faculty, Selcuk University, Konya, Turkey
| | - Azazahemad A Kureshi
- Department of Chemistry, Sardar Vallabhbhai National Institute of Technology, Surat, India
| | | | | | - Neeraj Rani
- Department of Pharmaceutical Sciences, Chaudhary Bansilal University, Bhiwani, Haryana, India
| | - Philippe Jeandet
- University of Reims, Research Unit Induced Resistance and Plant Bioprotection, USC INRAe 1488, Reims, France
| | - Monica Gulati
- School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH 1) Phagwara, Punjab 144411 India
| | - Bhupinder Kapoor
- School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH 1) Phagwara, Punjab 144411 India
| | - Yugal Kishore Mohanta
- Department of Applied Biology, School of Biological Sciences, University of Science and Technology Meghalaya (USTM), Techno City, Kling Road, Baridua, Ri-Bhoi, Meghalaya 793101, India
| | | | - Raphael Onuku
- Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nigeria
| | | | - Omar M Atrooz
- Department of Biological Sciences, Mutah University, Jordan
| | - Bey Hing Goh
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; Biofunctional Molecule Exploratory (BMEX) Research Group, School of Pharmacy, Monash University Malaysia, Subang Jaya, Malaysia
| | - Jose Carlos Andrade
- TOXRUN - Toxicology Research Unit, University Institute of Health Sciences, CESPU, Gandra, Portugal
| | | | - V J Shine
- Cancer Research Program, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala 695014, India
| | | | - Jamil Ahmad
- Department of Human Nutrition, The University of Agriculture Peshawar, Khyber Pakhtunkhwa, Pakistan
| | - Vivek K Chaturvedi
- Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India
| | | | - Rohit Sharma
- Department of Rasa Shastra and Bhaishajya Kalpana, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India
| | - Rupesh K Gautam
- Deparment of Pharmacology, Indore Institute of Pharmacy, IIST Campus, Rau-Indore-453331, India
| | - Sebastian Granica
- Microbiota Lab, Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Poland
| | - Salvatore Parisi
- Lourdes Matha Institute of Hotel Management and Catering Technology, Kerala State, India
| | - Rishabh Kumar
- School of Medical and Allied Sciences, K.R. Mangalam University, Sohna Road, Gurugram, Haryana 122103, India
| | - Atanas G Atanasov
- Ludwig Boltzmann Institute for Digital Health and Patient Safety, Medical University of Vienna, Spitalgasse 23, Vienna 1090, Austria; Department of Pharmaceutical Sciences, University of Vienna, Althanstraße 14, Vienna 1090, Austria; Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzebiec, Magdalenka 05-552, Poland.
| | - Bairong Shen
- Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Xinchuan Road 2222, Chengdu, Sichuan, China.
| |
Collapse
|
3
|
Engdahl CS, Tikhe CV, Dimopoulos G. Discovery of novel natural products for mosquito control. Parasit Vectors 2022; 15:481. [PMID: 36539851 PMCID: PMC9768913 DOI: 10.1186/s13071-022-05594-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Accepted: 11/17/2022] [Indexed: 12/24/2022] Open
Abstract
Vector control plays a key role in reducing the public health burden of mosquito-borne diseases. Today's vector control strategies largely rely on synthetic insecticides that can have a negative environmental impact when applied outdoors and often become inefficient because of the mosquitoes' ability to develop resistance. An alternative and promising approach to circumvent these challenges involves the implementation of insecticides derived from nature (biopesticides) for vector control. Biopesticides can constitute naturally occurring organisms or substances derived from them that have lifespan-shortening effects on disease vectors such as mosquitoes. Here we present the discovery and evaluation of natural product-based biological control agents that can potentially be developed into biopesticides for mosquito control. We screened a natural product collection comprising 390 compounds and initially identified 26 molecules with potential ability to kill the larval stages of the yellow fever mosquito Aedes aegypti, which is responsible for transmitting viruses such as dengue, Zika, chikungunya and yellow fever. Natural products identified as hits in the screen were further evaluated for their suitability for biopesticide development. We show that a selection of the natural product top hits, bactobolin, maytansine and ossamycin, also killed the larval stages of the malaria-transmitting mosquito Anopheles gambiae as well as the adult form of both species. We have further explored the usefulness of crude extracts and preparations from two of the best candidates' sources (organisms of origin) for mosquitocidal activity, that is extracts from the two bacteria Burkholderia thailandensis and Streptomyces hygroscopicus var. ossamyceticus.
Collapse
Affiliation(s)
- Cecilia S. Engdahl
- grid.21107.350000 0001 2171 9311W. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD USA ,grid.12650.300000 0001 1034 3451Present Address: Department of Clinical Microbiology, Virology, Umeå University, 90185 Umeå, Sweden
| | - Chinmay V. Tikhe
- grid.21107.350000 0001 2171 9311W. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD USA
| | - George Dimopoulos
- grid.21107.350000 0001 2171 9311W. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD USA
| |
Collapse
|
4
|
Dou J, Weathers P. Specialty molecules from plants and in vitro cultures as new drugs: regulatory considerations from flask to patient. PLANT CELL, TISSUE AND ORGAN CULTURE 2022; 149:105-111. [PMID: 35345535 PMCID: PMC8942155 DOI: 10.1007/s11240-022-02287-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2021] [Accepted: 03/15/2022] [Indexed: 05/13/2023]
Abstract
Few therapeutic specialty molecules from in vitro cultures beyond paclitaxel have come to market and although other more complex products like ginseng have also appeared, success has been limited. Often it is not the science that is limiting, but rather regulatory issues that limit considerations of potential products mainly because of costs in getting the product to market. Here we discuss broader thinking of such specialty molecules in the form of dietary supplements, nutraceuticals, herbal medicines, botanical drugs, and pure molecules along with potential complex products from a regulatory standpoint and especially within the realm of approved botanical drugs, e.g., Veregen and Fulyzaq, that have new drug applications (NDAs). The United States food and drug administration (US FDA) regulatory categories are used to provide examples of alternative product options that could prove useful for taking specialty molecules to market.
Collapse
Affiliation(s)
- Jinhui Dou
- Jiangsu Tripod Preclinical Research Laboratories Co. LTD, Nanjing, China
| | - Pamela Weathers
- Department of Biology and Biotechnology, Worcester Polytechnic Institute, 100 Institute Rd, Worcester, MA 01609 USA
| |
Collapse
|
5
|
Rodriguez-Gonzalez JC, Hernández-Balmaseda I, Declerck K, Pérez-Novo C, Logie E, Theys C, Jakubek P, Quiñones-Maza OL, Dantas-Cassali G, Carlos Dos Reis D, Van Camp G, Lopes Paz MT, Rodeiro-Guerra I, Delgado-Hernández R, Vanden Berghe W. Antiproliferative, Antiangiogenic, and Antimetastatic Therapy Response by Mangiferin in a Syngeneic Immunocompetent Colorectal Cancer Mouse Model Involves Changes in Mitochondrial Energy Metabolism. Front Pharmacol 2021; 12:670167. [PMID: 34924998 PMCID: PMC8678272 DOI: 10.3389/fphar.2021.670167] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 11/03/2021] [Indexed: 12/24/2022] Open
Abstract
In spite of the current advances and achievements in cancer treatments, colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. Drug resistance, adverse side effects and high rate of angiogenesis, metastasis and tumor relapse remain one of the greatest challenges in long-term management of CRC and urges need for new leads of anticancer drugs. We demonstrate that CRC treatment with the phytopharmaceutical mangiferin (MGF), a glucosylxanthone present in Mango tree stem bark and leaves (Mangifera Indica L.), induces dose-dependent tumor regression and decreases lung metastasis in a syngeneic immunocompetent allograft mouse model of murine CT26 colon carcinoma, which increases overall survival of mice. Antimetastatic and antiangiogenic MGF effects could be further validated in a wound healing in vitro model in human HT29 cells and in a matrigel plug implant mouse model. Interestingly, transcriptome pathway enrichment analysis demonstrates that MGF inhibits tumor growth, metastasis and angiogenesis by multi-targeting of mitochondrial oxidoreductase and fatty acid β-oxidation metabolism, PPAR, SIRT, NFκB, Stat3, HIF, Wnt and GP6 signaling pathways. MGF effects on fatty acid β-oxidation metabolism and carnitine palmitoyltransferase 1 (CPT1) protein expression could be further confirmed in vitro in human HT29 colon cells. In conclusion, antitumor, antiangiogenic and antimetastatic effects of MGF treatment hold promise to reduce adverse toxicity and to mitigate therapeutic outcome of colorectal cancer treatment by targeting mitochondrial energy metabolism in the tumor microenvironment.
Collapse
Affiliation(s)
| | | | - Ken Declerck
- Laboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, University of Antwerp, Campus Drie Eiken, Antwerp, Belgium
| | - Claudina Pérez-Novo
- Laboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, University of Antwerp, Campus Drie Eiken, Antwerp, Belgium
| | - Emilie Logie
- Laboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, University of Antwerp, Campus Drie Eiken, Antwerp, Belgium
| | - Claudia Theys
- Laboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, University of Antwerp, Campus Drie Eiken, Antwerp, Belgium
| | - Patrycja Jakubek
- Laboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, University of Antwerp, Campus Drie Eiken, Antwerp, Belgium.,Department of Food Chemistry, Technology and Biotechnology, Faculty of Chemistry, Gdansk University of Technology, Gdansk, Poland
| | | | - Geovanni Dantas-Cassali
- Departamento de Farmacología, Instituto de Ciencias Biológicas (ICB), Universidad Federal de Minas Gerais (UFMG), Horizonte, Brazil
| | - Diego Carlos Dos Reis
- Departamento de Farmacología, Instituto de Ciencias Biológicas (ICB), Universidad Federal de Minas Gerais (UFMG), Horizonte, Brazil
| | - Guy Van Camp
- Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium
| | - Miriam Teresa Lopes Paz
- Departamento de Farmacología, Instituto de Ciencias Biológicas (ICB), Universidad Federal de Minas Gerais (UFMG), Horizonte, Brazil
| | - Idania Rodeiro-Guerra
- Laboratorio de Farmacología, Instituto de Ciencias del Mar (ICIMAR), CITMA, La Habana, Cuba
| | - René Delgado-Hernández
- Centro de Estudios para las Investigaciones y Evaluaciones Biológicas (CEIEB), Instituto de Farmacia y Alimentos (IFAL), Universidad de La Habana, La Habana, Cuba.,Facultad de Ciencias Naturales y Agropecuarias, Universidat de Santander (UDES), Bucaramanga, Colombia
| | - Wim Vanden Berghe
- Laboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, University of Antwerp, Campus Drie Eiken, Antwerp, Belgium
| |
Collapse
|
6
|
Demarque DP, Espindola LS. Challenges, Advances and Opportunities in Exploring Natural Products to Control Arboviral Disease Vectors. Front Chem 2021; 9:779049. [PMID: 34869227 PMCID: PMC8634490 DOI: 10.3389/fchem.2021.779049] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 10/22/2021] [Indexed: 02/02/2023] Open
Abstract
Natural products constitute an important source of molecules for product development. However, despite numerous reports of compounds and active extracts from biodiversity, poor and developing countries continue to suffer with endemic diseases caused by arboviral vectors, including dengue, Zika, chikungunya and urban yellow fever. Vector control remains the most efficient disease prevention strategy. Wide and prolonged use of insecticides has resulted in vector resistance, making the search for new chemical prototypes imperative. Considering the potential of natural products chemistry for developing natural products-based products, including insecticides, this contribution discusses the general aspects and specific characteristics involved in the development of drug leads for vector control. Throughout this work, we highlight the obstacles that need to be overcome in order for natural products compounds to be considered promising prototypes. Moreover, we analyze the bottlenecks that should be addressed, together with potential strategies, to rationalize and improve the efficiency of the drug discovery process.
Collapse
Affiliation(s)
- Daniel P Demarque
- Laboratory of Pharmacognosy, Department of Pharmacy, Faculty of Health Sciences, University of Brasilia, Brasilia, Brazil.,Laboratory of Pharmacognosy, Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
| | - Laila S Espindola
- Laboratory of Pharmacognosy, Department of Pharmacy, Faculty of Health Sciences, University of Brasilia, Brasilia, Brazil
| |
Collapse
|
7
|
Bioactive Components of Salvia and Their Potential Antidiabetic Properties: A Review. Molecules 2021; 26:molecules26103042. [PMID: 34065175 PMCID: PMC8161164 DOI: 10.3390/molecules26103042] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 04/19/2021] [Accepted: 04/20/2021] [Indexed: 11/24/2022] Open
Abstract
The utilization of therapeutic plants is expanding around the globe, coupled with the tremendous expansion of alternative medicine and growing demand in health treatment. Plants are applied in pharmaceuticals to preserve and expand health—physically, mentally and as well as to treat particular health conditions and afflictions. There are more than 600 families of plants identified so far. Among the plants that are often studied for their health benefit include the genus of Salvia in the mint family, Lamiaceae. This review aims to determine the bioactive components of Salvia and their potential as antidiabetic agents. The search was conducted using three databases (PubMed, EMBASE and Scopus), and all relevant articles that are freely available in the English language were extracted within 10 years (2011–2021). Salvia spp. comprises many biologically active components that can be divided into monoterpenes, diterpenes, triterpenes, and phenolic components, but only a few of these have been studied in-depth for their health benefit claims. The most commonly studied bioactive component was salvianolic acids. Interestingly, S. miltiorrhiza is undoubtedly the most widely studied Salvia species in terms of its effectiveness as an antidiabetic agent. In conclusion, we hope that this review stimulates more studies on bioactive components from medicinal plants, not only on their potential as antidiabetic agents but also for other possible health benefits.
Collapse
|
8
|
Tompa DR, Immanuel A, Srikanth S, Kadhirvel S. Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. Int J Biol Macromol 2021; 172:524-541. [PMID: 33454328 PMCID: PMC8055758 DOI: 10.1016/j.ijbiomac.2021.01.076] [Citation(s) in RCA: 99] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 01/10/2021] [Accepted: 01/12/2021] [Indexed: 12/12/2022]
Abstract
The infectious microscopic viruses invade living cells to reproduce themselves, and causes chronic infections such as HIV/AIDS, hepatitis B and C, flu, etc. in humans which may lead to death if not treated. Different strategies have been utilized to develop new and superior antiviral drugs to counter the viral infections. The FDA approval of HIV nucleoside reverse transcriptase inhibitor, zidovudine in 1987 boosted the development of antiviral agents against different viruses. Currently, there are a number of combination drugs developed against various viral infections to arrest the activity of same or different viral macromolecules at multiple stages of its life cycle; among which majority are targeted to interfere with the replication of viral genome. Besides these, other type of antiviral molecules includes entry inhibitors, integrase inhibitors, protease inhibitors, interferons, immunomodulators, etc. The antiviral drugs can be toxic to human cells, particularly in case of administration of combination drugs, and on the other hand viruses can grow resistant to the antiviral drugs. Furthermore, emergence of new viruses like Ebola, coronaviruses (SARS-CoV, SARS-CoV-2) emphasizes the need for more innovative strategies to develop better antiviral drugs to fight the existing and the emerging viral infections. Hence, we reviewed the strategic enhancements in developing antiviral drugs for the treatment of different viral infections over the years.
Collapse
Affiliation(s)
- Dharma Rao Tompa
- Biomolecular Crystallography Laboratory, Department of Bioinformatics, School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur 613 401, Tamil Nadu, India
| | - Aruldoss Immanuel
- Biomolecular Crystallography Laboratory, Department of Bioinformatics, School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur 613 401, Tamil Nadu, India
| | - Srimari Srikanth
- Biomolecular Crystallography Laboratory, Department of Bioinformatics, School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur 613 401, Tamil Nadu, India
| | - Saraboji Kadhirvel
- Biomolecular Crystallography Laboratory, Department of Bioinformatics, School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur 613 401, Tamil Nadu, India.
| |
Collapse
|
9
|
Tauchen J, Huml L, Rimpelova S, Jurášek M. Flavonoids and Related Members of the Aromatic Polyketide Group in Human Health and Disease: Do They Really Work? Molecules 2020; 25:molecules25173846. [PMID: 32847100 PMCID: PMC7504053 DOI: 10.3390/molecules25173846] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 08/19/2020] [Accepted: 08/21/2020] [Indexed: 02/07/2023] Open
Abstract
Some aromatic polyketides such as dietary flavonoids have gained reputation as miraculous molecules with preeminent beneficial effects on human health, for example, as antioxidants. However, there is little conclusive evidence that dietary flavonoids provide significant leads for developing more effective drugs, as the majority appears to be of negligible medicinal importance. Some aromatic polyketides of limited distribution have shown more interesting medicinal properties and additional research should be focused on them. Combretastatins, analogues of phenoxodiol, hepatoactive kavalactones, and silymarin are showing a considerable promise in the advanced phases of clinical trials for the treatment of various pathologies. If their limitations such as adverse side effects, poor water solubility, and oral inactivity are successfully eliminated, they might be prime candidates for the development of more effective and in some case safer drugs. This review highlights some of the newer compounds, where they are in the new drug pipeline and how researchers are searching for additional likely candidates.
Collapse
Affiliation(s)
- Jan Tauchen
- Department of Food Science, Faculty of Agrobiology, Food and Natural Resources, Czech University of Life Sciences Prague, Kamýcká 129, Praha 6, 165 00 Praha, Czech Republic
- Correspondence: ; Tel.: +420-224-862-891
| | - Lukáš Huml
- Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 5, Prague 6, 166 28 Prague, Czech Republic; (L.H.); (M.J.)
| | - Silvie Rimpelova
- Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, Technická 3, Prague 6, 166 28 Prague, Czech Republic;
| | - Michal Jurášek
- Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 5, Prague 6, 166 28 Prague, Czech Republic; (L.H.); (M.J.)
| |
Collapse
|
10
|
Sharma S, Joshi R, Kumar D. Quantitative analysis of flavonols, flavonol glycoside and homoisoflavonoids in Polygonatum verticillatum using UHPLC-DAD-QTOF-IMS and evaluation of their antioxidant potential. PHYTOCHEMICAL ANALYSIS : PCA 2020; 31:333-339. [PMID: 31898384 DOI: 10.1002/pca.2899] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 10/14/2019] [Accepted: 10/18/2019] [Indexed: 06/10/2023]
Abstract
INTRODUCTION Polygonatum is widely used as a part of food in different regions of the world which covers five main categories such as drinks, vegetables, snacks, staple and seasoning foods. Presently, no analytical method is available for the quality control of Polygonatum. OBJECTIVE Development and validation of a method using ultrahigh-performance liquid chromatography diode array detector quadrupole time-of-flight (UHPLC-DAD/QTOF) technique for the estimation of six compounds including a flavonol glycoside [rutin (1)], two flavonols [quercetin (2) and kaempherol (3)] and three homoisoflavonoids [5,7-dihydroxy-3-(2-hydroxy-4-methoxybenzyl)-chroman-4-one (4), 5,7-dihydroxy-3-(2-hydroxy-4-methoxybenzyl)-8-methylchroman-4-one (5) and 5,7-dihydroxy-3-(4-methoxybenzyl)-8-methylchroman-4-one (6)]. In addition, screening of extract, fractions and compounds of P. verticillatum for antioxidant activity was also determined. METHODOLOGY The separation was achieved on C-18 column using acetonitrile and water containing 0.1% formic acid. The method was validated as per ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines. The validated method was applied for the simultaneous identification and quantification of compounds 1-6 in extract (E) and fractions (F1-F4) of P. verticillatum. Furthermore, antioxidant potential of E, F1 and F2 and compounds was evaluated using DPPH (2,2-diphenyl-1-picrylhydrazyl) assay. RESULTS The method was within the linear range (r2 ) of 0.982 to 0.999, precise (intra- and inter-day percentage relative standard deviations < 2.72 and 2.26) and accurate with recoveries (89.1-98.3%). The limit of detection and limit of quantification were in the ranges 0.02-0.16 and 0.06-0.48 ng/mL, respectively. Compounds 1-6 were quantified in all the samples. Compounds 1, 2 and 5 showed higher activity with half maximal inhibitory concentration (IC50 ) values 0.41, 0.39, 0.72 at 10, 20 and 30 μg/mL, respectively. CONCLUSION Developed method will be helpful to assess the quality of P. verticillatum raw material and their derived products.
Collapse
Affiliation(s)
- Shruti Sharma
- Academy of Scientific and Innovative Research, CSIR-Institute of Himalayan Bioresource Technology, Palampur176 061 (HP), India
- Natural Product Chemistry and Process Development Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur 176 061 (HP), India
| | - Robin Joshi
- Academy of Scientific and Innovative Research, CSIR-Institute of Himalayan Bioresource Technology, Palampur176 061 (HP), India
- Biotechnology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur 176 061 (HP), India
| | - Dinesh Kumar
- Academy of Scientific and Innovative Research, CSIR-Institute of Himalayan Bioresource Technology, Palampur176 061 (HP), India
- Natural Product Chemistry and Process Development Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur 176 061 (HP), India
| |
Collapse
|
11
|
Wu C, Lee SL, Taylor C, Li J, Chan YM, Agarwal R, Temple R, Throckmorton D, Tyner K. Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective. JOURNAL OF NATURAL PRODUCTS 2020; 83:552-562. [PMID: 31977211 DOI: 10.1021/acs.jnatprod.9b00949] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
The United States FDA has received over 800 botanical investigational new drug applications (IND) and pre-IND meeting requests (PIND) in the years preceding 2018. The current data show that indications for submitted INDs cover nearly every review division of the FDA. Despite increasing global interest in the investigation of botanical mixtures as drug products, only two botanical new drug applications (NDA) have been approved in the U.S.: Veregen in 2006 and Fulyzaq (also known as Mytesi) in 2012. Given botanicals' chemical and biological complexity, efforts in characterizing their pharmacology, demonstrating therapeutic efficacy, and ensuring quality consistency remain scientific and regulatory challenges. The FDA published a revised Botanical Drug Development Guidance for Industry document in December 2016 to address developmental considerations for late-phase trials and to provide recommendations intended to facilitate botanical drug development. Herein, we present an analysis of botanical INDs showing their variety of botanical raw materials (e.g., coming from different geographic regions, single vs multiple herbs), the varied levels of previous human experience, and therapeutic areas, as well as provide an overview of experience and challenges in reviewing botanical drugs.
Collapse
Affiliation(s)
- Charles Wu
- Botanical Review Team, Science Staff, Immediate Office, Office of Pharmaceutical Quality , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States
| | - Su-Lin Lee
- Science Staff, Immediate Office, Office of Pharmaceutical Quality , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States
| | - Cassandra Taylor
- Botanical Review Team, Science Staff, Immediate Office, Office of Pharmaceutical Quality , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States
| | - Jing Li
- Botanical Review Team, Science Staff, Immediate Office, Office of Pharmaceutical Quality , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States
| | - Yen-Ming Chan
- Botanical Review Team, Science Staff, Immediate Office, Office of Pharmaceutical Quality , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States
| | - Rajiv Agarwal
- New Drug Products Branch II, Division of New Drug Products I, Office of New Drug Products, Office of Pharmaceutical Quality , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States
| | - Robert Temple
- Office of the Center Director , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States
| | - Douglas Throckmorton
- Office of the Center Director , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States
| | - Katherine Tyner
- Science Staff, Immediate Office, Office of Pharmaceutical Quality , Center for Drug Evaluation and Research, Food and Drug Administration , 10903 New Hampshire Avenue , Silver Spring , Maryland 20993 , United States
| |
Collapse
|
12
|
Wang SJ, Wang XH, Dai YY, Ma MH, Rahman K, Nian H, Zhang H. Prunella vulgaris: A Comprehensive Review of Chemical Constituents, Pharmacological Effects and Clinical Applications. Curr Pharm Des 2020; 25:359-369. [PMID: 30864498 DOI: 10.2174/1381612825666190313121608] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 03/08/2019] [Indexed: 12/17/2022]
Abstract
Prunella vulgaris (PV) is a perennial herb belonging to the Labiate family and is widely distributed in the northeastern Asian countries such as Korea, Japan, and China. It is reported to display diverse biological activities including anti-microbial, anti-cancer, and anti-inflammation as determined by in vitro or in vivo studies. So far, about 200 compounds have been isolated from PV plant and a majority of these have been characterized mainly as triterpenoids, sterols and flavonoids, followed by coumarins, phenylpropanoids, polysaccharides and volatile oils. This review summarizes and analyzes the current knowledge on the chemical constituents, pharmacological activities, mechanisms of action and clinical applications of the PV plant including its potential as a future medicinal plant. Although some of the chemical constituents of the PV plant and their mechanisms of action have been investigated, the biological activities of many of these remain unknown and further clinical trials are required to further enhance its reputation as a medicinal plant.
Collapse
Affiliation(s)
- Su-Juan Wang
- Pharmaceutical Center of Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.,Department of Drug Preparation, Hospital of TCM and Hui Nationality Medicine, Ningxia Medical University, Ningxia 751100, China
| | - Xiao-He Wang
- Pharmaceutical Center of Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
| | - Yuan-Yuan Dai
- Pharmaceutical Center of Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
| | - Ming-Hua Ma
- Department of Pharmacy, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, China
| | - Khalid Rahman
- School of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John Moores University, Liverpool L3 3AF, England, United Kingdom
| | - Hua Nian
- Pharmaceutical Center of Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
| | - Hong Zhang
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| |
Collapse
|
13
|
A strategy for the metabolomics-based screening of active constituents and quality consistency control for natural medicinal substance toad venom. Anal Chim Acta 2018; 1031:108-118. [DOI: 10.1016/j.aca.2018.05.054] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 04/18/2018] [Accepted: 05/20/2018] [Indexed: 01/20/2023]
|
14
|
White JD, Lin H, Jia L, Wu RS, Lam S, Li J, Dou J, Kumar N, Lin L, Lao L. Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer. J Glob Oncol 2017; 3:814-822. [PMID: 29244995 PMCID: PMC5735960 DOI: 10.1200/jgo.2016.005710] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
On November 3, 2014, in Bethesda, MD, the Office of Cancer Complementary and Alternative Medicine of the National Cancer Institute held a meeting to examine the potential utility and feasibility of establishing an international consortium for Chinese medicine and cancer. There is significant interest in the West in using components of Chinese medicine (CM) -such as botanicals and herbal medicines, acupuncture and acupressure, and qigong-in the field of oncology, as potential anticancer agents, for symptom management, and to improve quality of life. The proposal for a consortium on CM came from the Chinese Academy of Chinese Medical Sciences, with the aims of improving scientific communications and collaborations and modernizing the studies of CM for cancer. The US National Cancer Institute's Office of Cancer Complementary and Alternative Medicine agreed to work with Chinese Academy of Chinese Medical Sciences to explore the feasibility of establishing an international consortium for Chinese medicine and cancer. At the meeting, participants from the United States, China, Canada, Australia, and Korea discussed issues in CM and cancer research, treatment, and management, including potential mechanisms of action, proof of efficacy, adverse effects, regulatory issues, and the need for improving the quality of randomized clinical trials of CM treatments and supportive care interventions. Presented in these proceedings are some of the main issues and opportunities discussed by workshop participants.
Collapse
Affiliation(s)
- Jeffrey D. White
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Hongsheng Lin
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Libin Jia
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Roy S. Wu
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Stephen Lam
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Jie Li
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Jinhui Dou
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Nagi Kumar
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Lizhu Lin
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| | - Lixing Lao
- Jeffrey D. White, Libin Jia, and Roy S. Wu, National Cancer Institute, Rockville; Jinhui Dou, Food and Drug Administration, Silver Spring, MD; Hongsheng Lin and Jie Li, China Academy of Chinese Medical Sciences, Beijing; Lizhu Lin, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou; Lixing Lao, The University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, People’s Republic of China; Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and Nagi Kumar, Moffitt Cancer Center, University of South Florida, Tampa, FL
| |
Collapse
|
15
|
Lee KM, Jeon JY, Lee BJ, Lee H, Choi HK. Application of Metabolomics to Quality Control of Natural Product Derived Medicines. Biomol Ther (Seoul) 2017; 25:559-568. [PMID: 28605829 PMCID: PMC5685424 DOI: 10.4062/biomolther.2016.249] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Revised: 03/21/2017] [Accepted: 03/30/2017] [Indexed: 11/21/2022] Open
Abstract
Metabolomics has been used as a powerful tool for the analysis and quality assessment of the natural product (NP)-derived medicines. It is increasingly being used in the quality control and standardization of NP-derived medicines because they are composed of hundreds of natural compounds. The most common techniques that are used in metabolomics consist of NMR, GC-MS, and LC-MS in combination with multivariate statistical analyses including principal components analysis (PCA) and partial least squares-discriminant analysis (PLS-DA). Currently, the quality control of the NP-derived medicines is usually conducted using HPLC and is specified by one or two indicators. To create a superior quality control framework and avoid adulterated drugs, it is necessary to be able to determine and establish standards based on multiple ingredients using metabolic profiling and fingerprinting. Therefore, the application of various analytical tools in the quality control of NP-derived medicines forms the major part of this review. Veregen® (Medigene AG, Planegg/Martinsried, Germany), which is the first botanical prescription drug approved by US Food and Drug Administration, is reviewed as an example that will hopefully provide future directions and perspectives on metabolomics technologies available for the quality control of NP-derived medicines.
Collapse
Affiliation(s)
- Kyung-Min Lee
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea
| | - Jun-Yeong Jeon
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea
| | - Byeong-Ju Lee
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea
| | - Hwanhui Lee
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea
| | - Hyung-Kyoon Choi
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea
| |
Collapse
|
16
|
Bernardini S, Tiezzi A, Laghezza Masci V, Ovidi E. Natural products for human health: an historical overview of the drug discovery approaches. Nat Prod Res 2017; 32:1926-1950. [DOI: 10.1080/14786419.2017.1356838] [Citation(s) in RCA: 96] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
- S. Bernardini
- Laboratory of Plant Cytology and Biotechnology, Department for the Innovation in Biological, Agrofood and Forestal Systems (DIBAF), Tuscia University, Viterbo, Italy
| | - A. Tiezzi
- Laboratory of Plant Cytology and Biotechnology, Department for the Innovation in Biological, Agrofood and Forestal Systems (DIBAF), Tuscia University, Viterbo, Italy
| | - V. Laghezza Masci
- Laboratory of Plant Cytology and Biotechnology, Department for the Innovation in Biological, Agrofood and Forestal Systems (DIBAF), Tuscia University, Viterbo, Italy
| | - E. Ovidi
- Laboratory of Plant Cytology and Biotechnology, Department for the Innovation in Biological, Agrofood and Forestal Systems (DIBAF), Tuscia University, Viterbo, Italy
| |
Collapse
|
17
|
Chakraborty S, Kar N, Kumari L, De A, Bera T. Inhibitory effect of a new orally active cedrol-loaded nanostructured lipid carrier on compound 48/80-induced mast cell degranulation and anaphylactic shock in mice. Int J Nanomedicine 2017; 12:4849-4868. [PMID: 28744120 PMCID: PMC5511028 DOI: 10.2147/ijn.s132114] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND Type I hypersensitivity is an allergic reaction characterized by the overactivity of the immune system provoked by normally harmless substances. Glucocorticoids, anti-histamines, or mast cell stabilizers are the choices of treatment for type I hypersensitivity. Even though these drugs have the anti-allergic effect, they can have several side effects in prolong use. Cedrol is the main bioactive compound of Cedrus atlantica with anti-tumor, anti-oxidative, and platelet-activating factor inhibiting properties. METHODS In this study, the preparation and anti-anaphylactic effect of cedrol-loaded nanostructured lipid carriers (NLCs) were evaluated. NLCs were prepared using Compritol® 888 ATO and triolein as lipid phase and vitamin E d-α-tocopherylpolyethyleneglycol 1000 succinate, soya lecithin, and sodium deoxycholate as nanoparticle stabilizers. RESULTS The average diameter of cedrol-NLCs (CR-NLCs) was 71.2 nm (NLC-C1) and 91.93 nm (NLC-C2). The particle had negative zeta potential values of -31.9 mV (NLC-C1) and -44.5 mV (NLC-C2). Type I anaphylactoid reaction in the animal model is significantly reduced by cedrol and cedrol-NLC. This in vivo activity of cedrol resulted that cedrol suppressed compound 48/80-induced peritoneal mast cell degranulation and histamine release from mast cells. Furthermore, compound 48/80-evoked Ca2+ uptake into mast cells was reduced in a dose-dependent manner by cedrol and cedrol-NLC. Studies confirmed that the inhibition of type I anaphylactoid response in vivo in mice and compound 48/80-induced mast cell activation in vitro are greatly enhanced by the loading of cedrol into the NLCs. The safety of cedrol and CR-NLC was evaluated as selectivity index (SI) with prednisolone and cromolyn sodium as positive control. SI of CR-NLC-C2 was found to be 11.5-fold greater than both prednisolone and cromolyn sodium. CONCLUSION Administration of CR-NLC 24 hours before the onset of anaphylaxis can prevent an anaphylactoid reaction. NLCs could be a promising vehicle for the oral delivery of cedrol to protect anaphylactic reactions.
Collapse
Affiliation(s)
- Shreyasi Chakraborty
- Laboratory of Nanomedicine, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| | - Nabanita Kar
- Laboratory of Nanomedicine, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| | - Leena Kumari
- Laboratory of Nanomedicine, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| | - Asit De
- Laboratory of Nanomedicine, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| | - Tanmoy Bera
- Laboratory of Nanomedicine, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| |
Collapse
|
18
|
Cui Y, Shen N, Dang J, Mei L, Tao Y, Liu Z. Anti-inflammatory bioactive equivalence of combinatorial components β-carboline alkaloids identified in Arenaria kansuensis
by two-dimensional chromatography and solid-phase extraction coupled with liquid-liquid extraction enrichment technology. J Sep Sci 2017; 40:2895-2905. [DOI: 10.1002/jssc.201700144] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 04/10/2017] [Accepted: 05/03/2017] [Indexed: 11/08/2022]
Affiliation(s)
- Yulei Cui
- Northwest Institute of Plateau Biology; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research of Qinghai Province; Xining Qinghai P.R. China
- University of Chinese Academy of Sciences; Beijing P.R. China
| | - Na Shen
- Northwest Institute of Plateau Biology; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research of Qinghai Province; Xining Qinghai P.R. China
- University of Chinese Academy of Sciences; Beijing P.R. China
| | - Jun Dang
- Northwest Institute of Plateau Biology; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research of Qinghai Province; Xining Qinghai P.R. China
| | - Lijuan Mei
- Northwest Institute of Plateau Biology; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research of Qinghai Province; Xining Qinghai P.R. China
| | - Yanduo Tao
- Northwest Institute of Plateau Biology; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research of Qinghai Province; Xining Qinghai P.R. China
| | - Zenggen Liu
- Northwest Institute of Plateau Biology; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research; Chinese Academy of Sciences; Xining Qinghai P.R. China
- Key Laboratory of Tibetan Medicine Research of Qinghai Province; Xining Qinghai P.R. China
| |
Collapse
|
19
|
Kar N, Chakraborty S, De AK, Ghosh S, Bera T. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes. Eur J Pharm Sci 2017; 104:196-211. [PMID: 28400285 DOI: 10.1016/j.ejps.2017.03.046] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Revised: 03/30/2017] [Accepted: 03/31/2017] [Indexed: 12/28/2022]
Abstract
Leishmaniasis is an epidemic in various countries, and the parasite Leishmania donovani is developing resistance against available drugs. In the present study the antileishmanial action of cedrol was evaluated in vitro and in vivo. Activity potentiation was achieved via nanostructured lipid carrier (NLC) complexation of cedrol. Cedrol-loaded NLC was prepared through the hot-melting emulsification-ultrasonication method. The cedrol- NLC prepared did not require the use of any organic solvents. The characterization of NLC-C1 and NLC-C2 revealed that particle size was 46.62nm and 54.73nm for 3.85%, and 7.48% drug loading, respectively and negative charge of -19.2mV and -23.7mV. The cedrol-loaded NLC were found to be spherical with a smooth surface. Drug-carrier interactions were clearly visualized in FT-IR studies. Incorporation of cedrol in NLC was ascertained in DSC and XRD analysis. Antileishmanial activities of free cedrol and cedrol-NLC were performed against L. donovani wild-type, sodium stibogluconate, paromomycin and field isolated resistant strains in axenic amastigotes and amastigotes in macrophage model. Coumarin-6 loaded NLC nanoparticles were assessed for macrophage internalization in confocal microscopic studies. Cedrol showed significant antileishmanial activity in wild-type (IC50=1.5μM), sodium stibogluconate resistant (IC50=2μM), paromomycin resistant (IC50=1.8μM) and field isolated resistant (IC50=1.35μM) strains in macrophage together with cytotoxicity (CC50=74μM) in mouse peritoneal macrophage cells. Incorporation of cedrol in NLC-C2 resulted in 2.1-fold and 2-fold increase in selectivity indexes (CC50/IC50) for wild-type and drug resistant strains, respectively. In addition, in vivo studies revealed that bioactivity of NLC-C2 were 2.3 to 3.8-fold increased in wild-type and 3 to 4.9-fold increased in drug resistant strains when compared with free cedrol; administered orally in mouse leishmaniasis model. Overall, NLC-C2 showed superior antileishmanial activity to free cedrol and miltefosine in oral dose. These findings support the use of NLCs for oral delivery of poorly water-soluble antileishmanial drugs in treatment of leishmaniasis. CHEMICAL COMPOUNDS Cedrol (PubChem CID: 65575); Compritol® 888 ATO (PubChem CID: 62726); Triolein (PubChem CID: 5497163); Pluronic F68 (PubChem CID: 24751); Soya lecithin (PubChem CID: 57369748); Sodium deoxycholate (PubChem CID: 23668196); Miltefosine (PubChem CID: 3599); Paromomycin (PubChem CID: 165580); Amphotericin B (PubChem CID: 5280965); Sodium stibogluconate (PubChem CID: 16683012).
Collapse
Affiliation(s)
- Nabanita Kar
- Laboratory of Nanomedicine, Division of Pharmaceutical Biotechnology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
| | - Shreyasi Chakraborty
- Laboratory of Nanomedicine, Division of Pharmaceutical Biotechnology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
| | - Asit Kumar De
- Laboratory of Nanomedicine, Division of Pharmaceutical Biotechnology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
| | - Santanu Ghosh
- Laboratory of Nanomedicine, Division of Pharmaceutical Biotechnology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
| | - Tanmoy Bera
- Laboratory of Nanomedicine, Division of Pharmaceutical Biotechnology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India.
| |
Collapse
|
20
|
Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements. BIOMED RESEARCH INTERNATIONAL 2017; 2017:8412508. [PMID: 28232946 PMCID: PMC5292383 DOI: 10.1155/2017/8412508] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Revised: 12/09/2016] [Accepted: 12/27/2016] [Indexed: 12/17/2022]
Abstract
Pancreatic cancer is a type of common malignant tumors with high occurrence in the world. Most patients presented in clinic had pancreatic cancer at advanced stages. Furthermore, chemotherapy or radiotherapy had very limited success in treating pancreatic cancer. Complementary and alternative medicines, such as natural products/herbal medicines, represent exciting adjunctive therapies. In this review, we summarize the recent advances of using natural products/herbal medicines, such as Chinese herbal medicine, in combination with conventional chemotherapeutic agents to treat pancreatic cancer in preclinical and clinical trials.
Collapse
|
21
|
Development of colorimetric sensor array for discrimination of herbal medicine. JOURNAL OF THE IRANIAN CHEMICAL SOCIETY 2016. [DOI: 10.1007/s13738-016-1008-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
22
|
Abstract
Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2'-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox). Here, we present for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.
Collapse
Affiliation(s)
- Erik De Clercq
- KU Leuven-University of Leuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Leuven, Belgium
| | - Guangdi Li
- KU Leuven-University of Leuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Leuven, Belgium Department of Metabolism and Endocrinology, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
| |
Collapse
|
23
|
In Vitro susceptibilities of wild and drug resistant Leishmania donovani amastigotes to piperolactam A loaded hydroxypropyl-β-cyclodextrin nanoparticles. Acta Trop 2016; 158:97-106. [PMID: 26940000 DOI: 10.1016/j.actatropica.2016.02.017] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Revised: 02/25/2016] [Accepted: 02/26/2016] [Indexed: 11/20/2022]
Abstract
Leishmaniasis is an epidemic in various countries, and the parasite Leishmania donovani is developing resistance against available drugs. In the present study the antileishmanial action of piperolactam A (PL), isolated after bioactivity guided fractionation from root extracts of Piper betle was accentuated in detail. Activity potentiation was achieved via cyclodextrin complexation. Crude hydro-ethanolic extract (PB) and three fractions obtained from PB and fabricated PL-hydroxypropyl-β-cyclodextrin (HPBCD) nanoparticles were evaluated for antileishmanial activity. Tests were performed against L. donovani wild-type, sodium stibogluconate, paromomycin and field isolated (GE1) resistant strains in axenic amastigote and amastigote in macrophage models. PL-HPBCD complex was characterized and FITC loaded HPBCD nanoparticles were assessed for macrophage internalization in confocal microscopic studies. Isolated and purified PL from most potent, alkaloid rich ethyl acetate fraction of PB showed high level of antileishmanial activities in wild-type (IC50=36 μM), sodium stibogluconate resistant (IC50=103 μM), paromomycin resistant (IC50=91 μM) and field isolated resistant (IC50=72 μM) strains together with cytotoxicity (CC50=900 μM) in mouse peritoneal macrophage cells. Inclusion of PL in HPBCD nanoparticles resulted in 10-fold and 4-10-fold increase in selectivity indexes (CC50/IC50) for wild-type and drug resistant strains, respectively. Drug-carrier interactions were clearly visualized in FT-IR studies. Complete incorporation of PL in HPBCD cavity was ascertained in DSC and XRD analyses. 180nm size stable nanospheres showed macrophage internalization within 1h of incubation. Piperolactam A (PL), a representative of the inchoate skeleton of aristolactam chassis might be the source of safe and affordable antileishmanial agents for the cure of deadly Leishmania infections.
Collapse
|
24
|
Withania somnifera Induces Cytotoxic and Cytostatic Effects on Human T Leukemia Cells. Toxins (Basel) 2016; 8:toxins8050147. [PMID: 27187469 PMCID: PMC4885062 DOI: 10.3390/toxins8050147] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Revised: 04/29/2016] [Accepted: 05/09/2016] [Indexed: 12/12/2022] Open
Abstract
Cancer chemotherapy is characterized by an elevated intrinsic toxicity and the development of drug resistance. Thus, there is a compelling need for new intervention strategies with an improved therapeutic profile. Immunogenic cell death (ICD) represents an innovative anticancer strategy where dying cancer cells release damage-associated molecular patterns promoting tumor-specific immune responses. The roots of Withania somnifera (W. somnifera) are used in the Indian traditional medicine for their anti-inflammatory, immunomodulating, neuroprotective, and anticancer activities. The present study is designed to explore the antileukemic activity of the dimethyl sulfoxide extract obtained from the roots of W. somnifera (WE). We studied its cytostatic and cytotoxic activity, its ability to induce ICD, and its genotoxic potential on a human T-lymphoblastoid cell line by using different flow cytometric assays. Our results show that WE has a significant cytotoxic and cytostatic potential, and induces ICD. Its proapoptotic mechanism involves intracellular Ca2+ accumulation and the generation of reactive oxygen species. In our experimental conditions, the extract possesses a genotoxic potential. Since the use of Withania is suggested in different contexts including anti-infertility and osteoarthritis care, its genotoxicity should be carefully considered for an accurate assessment of its risk–benefit profile.
Collapse
|
25
|
Avigan MI, Mozersky RP, Seeff LB. Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States. Int J Mol Sci 2016; 17:331. [PMID: 26950122 PMCID: PMC4813193 DOI: 10.3390/ijms17030331] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 02/16/2016] [Accepted: 02/16/2016] [Indexed: 01/06/2023] Open
Abstract
In the United States (US), the risk of hepatotoxicity linked to the widespread use of certain herbal products has gained increased attention among regulatory scientists. Based on current US law, all dietary supplements sold domestically, including botanical supplements, are regulated by the Food and Drug Administration (FDA) as a special category of foods. Under this designation, regulatory scientists do not routinely evaluate the efficacy of these products prior to their marketing, despite the content variability and phytochemical complexity that often characterizes them. Nonetheless, there has been notable progress in the development of advanced scientific methods to qualitatively and quantitatively measure ingredients and screen for contaminants and adulterants in botanical products when hepatotoxicity is recognized.
Collapse
Affiliation(s)
- Mark I Avigan
- Office of Pharmacovigilance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
| | - Robert P Mozersky
- Office of Dietary Supplement Products, Center for Food Safety and Applied Nutrition, 5100 Paint Branch Parkway, College Park, MD 20740, USA.
| | | |
Collapse
|
26
|
Sponchiado G, Adam ML, Silva CD, Soley BS, de Mello-Sampayo C, Cabrini DA, Correr CJ, Otuki MF. Quantitative genotoxicity assays for analysis of medicinal plants: A systematic review. JOURNAL OF ETHNOPHARMACOLOGY 2016; 178:289-296. [PMID: 26680588 DOI: 10.1016/j.jep.2015.10.026] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Revised: 10/17/2015] [Accepted: 10/17/2015] [Indexed: 06/05/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Medicinal plants are known to contain numerous biologically active compounds, and although they have proven pharmacological properties, they can cause harm, including DNA damage. AIM OF THE STUDY Review the literature to evaluate the genotoxicity risk of medicinal plants, explore the genotoxicity assays most used and compare these to the current legal requirements. MATERIAL AND METHODS A quantitative systematic review of the literature, using the keywords "medicinal plants", "genotoxicity" and "mutagenicity", was undertakenQ to identify the types of assays most used to assess genotoxicity, and to evaluate the genotoxicity potential of medicinal plant extracts. RESULTS The database searches retrieved 2289 records, 458 of which met the inclusion criteria. Evaluation of the selected articles showed a total of 24 different assays used for an assessment of medicinal plant extract genotoxicity. More than a quarter of those studies (28.4%) reported positive results for genotoxicity. CONCLUSIONS This review demonstrates that a range of genotoxicity assay methods are used to evaluate the genotoxicity potential of medicinal plant extracts. The most used methods are those recommended by regulatory agencies. However, based on the current findings, in order to conduct a thorough study concerning the possible genotoxic effects of a medicinal plant, we indicate that it is important always to include bacterial and mammalian tests, with at least one in vivo assay. Also, these tests should be capable of detecting outcomes that include mutation induction, clastogenic and aneugenic effects, and structural chromosome abnormalities. In addition, the considerable rate of positive results detected in this analysis further supports the relevance of assessing the genotoxicity potential of medicinal plants.
Collapse
Affiliation(s)
- Graziela Sponchiado
- Departamento de Ciências Farmacêuticas, Universidade Federal do Paraná, Curitiba, PR, Brazil
| | | | - Caroline Dadalt Silva
- Departamento de Farmacologia, Universidade Federal do Paraná, Centro Politécnico, Curitiba, Brazil
| | - Bruna Silva Soley
- Departamento de Farmacologia, Universidade Federal do Paraná, Centro Politécnico, Curitiba, Brazil
| | | | - Daniela Almeida Cabrini
- Departamento de Farmacologia, Universidade Federal do Paraná, Centro Politécnico, Curitiba, Brazil
| | | | - Michel Fleith Otuki
- Departamento de Farmacologia, Universidade Federal do Paraná, Centro Politécnico, Curitiba, Brazil; Departamento de Ciências Farmacêuticas, Universidade Estadual de Ponta Grossa, Ponta Grossa, PR, Brazil.
| |
Collapse
|
27
|
Abstract
Botanicals are ingredients that can be marketed as foods, drugs, cosmetics, and medical devices in the United States. When a botanical is intended to diagnose, treat, prevent, mitigate, or cure a disease, it is considered to be a "drug". This article reviews the US regulatory requirements for botanicals as "new" drugs. An overview of the regulatory principles used to determine product category and the basic elements of an Investigational New Drug application and New Drug Application with the US Food and Drug Administration are presented. This article is part of a Special Issue entitled "Botanicals for Epilepsy".
Collapse
|
28
|
Wiesner J, Knöss W. Future visions for traditional and herbal medicinal products--a global practice for evaluation and regulation? JOURNAL OF ETHNOPHARMACOLOGY 2014; 158 Pt B:516-518. [PMID: 25152297 DOI: 10.1016/j.jep.2014.08.015] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/15/2014] [Revised: 08/11/2014] [Accepted: 08/12/2014] [Indexed: 06/03/2023]
Abstract
Medicinal plants and traditional medicines have been used worldwide since ancient times. Currently, there is neither a globally consented terminology nor a harmonized regulatory approach. Nevertheless, it is common sense that quality, efficacy and safety should be assessed following scientific standards, addressing particulars and considering an adequate level of risk management. A global market for traditional medicines is emerging, if not already existing. Therefore, a constructive communication about regulatory systems for herbal and traditional medicinal products should be enforced. Best practice standards might be developed according to current scientific knowledge in order to improve mutual acceptance of data, sets of monographs and assessments. Overall, a convergence of the diverse regulatory systems might save resources and lead to an adequate availability of herbal and traditional medicinal products to the patients without neglecting public health.
Collapse
Affiliation(s)
- Jacqueline Wiesner
- Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, Bonn 53175, Germany
| | - Werner Knöss
- Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, Bonn 53175, Germany.
| |
Collapse
|
29
|
Pérez LB, Still PC, Naman CB, Ren Y, Pan L, Chai HB, Carcache de Blanco EJ, Ninh TN, Van Thanh B, Swanson SM, Soejarto DD, Kinghorn AD. Investigation of Vietnamese plants for potential anticancer agents. PHYTOCHEMISTRY REVIEWS : PROCEEDINGS OF THE PHYTOCHEMICAL SOCIETY OF EUROPE 2014; 13:727-739. [PMID: 25395897 PMCID: PMC4225705 DOI: 10.1007/s11101-014-9335-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Higher plants continue to afford humankind with many new drugs, for a variety of disease types. In this review, recent phytochemical and biological progress is presented for part of a collaborative multi-institutional project directed towards the discovery of new antitumor agents. The specific focus is on bioactive natural products isolated and characterized structurally from tropical plants collected in Vietnam. The plant collection, identification, and processing steps are described, and the natural products isolated from these species are summarized with their biological activities.
Collapse
Affiliation(s)
- Lynette Bueno Pérez
- College of Pharmacy, The Ohio State University, 500 West 12 Avenue, Columbus, OH 43210, USA
| | - Patrick C Still
- College of Pharmacy, The Ohio State University, 500 West 12 Avenue, Columbus, OH 43210, USA
| | - C Benjamin Naman
- College of Pharmacy, The Ohio State University, 500 West 12 Avenue, Columbus, OH 43210, USA
| | - Yulin Ren
- College of Pharmacy, The Ohio State University, 500 West 12 Avenue, Columbus, OH 43210, USA
| | - Li Pan
- College of Pharmacy, The Ohio State University, 500 West 12 Avenue, Columbus, OH 43210, USA
| | - Hee-Byung Chai
- College of Pharmacy, The Ohio State University, 500 West 12 Avenue, Columbus, OH 43210, USA
| | | | - Tran Ngoc Ninh
- Institute of Ecology and Biological Resources, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Cau Giay, Hanoi, Vietnam
| | - Bui Van Thanh
- Institute of Ecology and Biological Resources, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Cau Giay, Hanoi, Vietnam
| | - Steven M Swanson
- College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA
| | - Djaja D Soejarto
- College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA. Department of Botany, Field Museum, 1400 South Lake Shore Drive, Chicago, IL 60605, USA
| | - A Douglas Kinghorn
- College of Pharmacy, The Ohio State University, 500 West 12 Avenue, Columbus, OH 43210, USA
| |
Collapse
|
30
|
Review of the regulations for clinical research in herbal medicines in USA. Chin J Integr Med 2014; 20:883-93. [PMID: 25428336 DOI: 10.1007/s11655-014-2024-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2014] [Indexed: 01/17/2023]
Abstract
In 2012, USA Food and Drug Administration (FDA) approved 39 new drugs, however, there are only two botanical drugs (one topical and one oral) approved by FDA since the publication of the FDA's industry guidelines for the botanical drug product in June 2004. The approval shows the Western guideline can be used for herbal medicines, authors investigate current regulation on herbal medicine clinical research, identify challenges conducting clinical trials, and seek to produce some guidance for potential investigators and sponsors considering a clinical trial in this area. Key words were formulated for searching on Medline and FDA website to locate relevant regulations for clinical research in herbal medicines to understand current environment for herbal medicine usage and examine the barriers affecting herbal medicine in clinical trials. Authors critically explore case study of the 1st FDA approved botanical drugs, Veregen (sinecatechins), green tea leaves extract, a topical cream for perianal and genital condyloma. In consideration of current regulation environment in USA, based on the findings and analysis through the literature review and Veregen case study, authors produce and propose a Checklist for New Drug Application of Herbal Medicines for potential investigators and sponsors considering in a herbal medicine clinical trial.
Collapse
|
31
|
Chemical investigation of the medicinal and ornamental plant Angelonia angustifolia Benth. reveals therapeutic quantities of lupeol. Fitoterapia 2014; 98:174-8. [DOI: 10.1016/j.fitote.2014.08.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Accepted: 08/03/2014] [Indexed: 01/11/2023]
|
32
|
Yue Y, Chu GX, Liu XS, Tang X, Wang W, Liu GJ, Yang T, Ling TJ, Wang XG, Zhang ZZ, Xia T, Wan XC, Bao GH. TMDB: a literature-curated database for small molecular compounds found from tea. BMC PLANT BIOLOGY 2014; 14:243. [PMID: 25224438 PMCID: PMC4172869 DOI: 10.1186/s12870-014-0243-1] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Accepted: 09/08/2014] [Indexed: 05/08/2023]
Abstract
BACKGROUND Tea is one of the most consumed beverages worldwide. The healthy effects of tea are attributed to a wealthy of different chemical components from tea. Thousands of studies on the chemical constituents of tea had been reported. However, data from these individual reports have not been collected into a single database. The lack of a curated database of related information limits research in this field, and thus a cohesive database system should necessarily be constructed for data deposit and further application. DESCRIPTION The Tea Metabolome database (TMDB), a manually curated and web-accessible database, was developed to provide detailed, searchable descriptions of small molecular compounds found in Camellia spp. esp. in the plant Camellia sinensis and compounds in its manufactured products (different kinds of tea infusion). TMDB is currently the most complete and comprehensive curated collection of tea compounds data in the world. It contains records for more than 1393 constituents found in tea with information gathered from 364 published books, journal articles, and electronic databases. It also contains experimental 1H NMR and 13C NMR data collected from the purified reference compounds or collected from other database resources such as HMDB. TMDB interface allows users to retrieve tea compounds entries by keyword search using compound name, formula, occurrence, and CAS register number. Each entry in the TMDB contains an average of 24 separate data fields including its original plant species, compound structure, formula, molecular weight, name, CAS registry number, compound types, compound uses including healthy benefits, reference literatures, NMR, MS data, and the corresponding ID from databases such as HMDB and Pubmed. Users can also contribute novel regulatory entries by using a web-based submission page. The TMDB database is freely accessible from the URL of http://pcsb.ahau.edu.cn:8080/TCDB/index.jsp. The TMDB is designed to address the broad needs of tea biochemists, natural products chemists, nutritionists, and members of tea related research community. CONCLUSION The TMDB database provides a solid platform for collection, standardization, and searching of compounds information found in tea. As such this database will be a comprehensive repository for tea biochemistry and tea health research community.
Collapse
Affiliation(s)
- Yi Yue
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Gang-Xiu Chu
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Xue-Shi Liu
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Xing Tang
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Wei Wang
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Guang-Jin Liu
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Tao Yang
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Tie-Jun Ling
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Xiao-Gang Wang
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Zheng-Zhu Zhang
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Tao Xia
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Xiao-Chun Wan
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| | - Guan-Hu Bao
- Key Laboratory of Tea Biochemistry and Biotechnology, Anhui Agricultural University, 130 West Changjiang Road, Hefei, Anhui Province 230036 China
| |
Collapse
|
33
|
Pelkonen O, Xu Q, Fan TP. Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality? J Tradit Complement Med 2014; 4:1-7. [PMID: 24872927 PMCID: PMC4032837 DOI: 10.4103/2225-4110.124323] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Research on herbal medicinal products is increasingly published in “Western” scientific journals dedicated primarily to conventional medicines. Publications are concerned mainly not only on the issues of safety and interactions, but also on efficacy. In reviews, a recurring complaint has been a lack of quality studies. In this opinion article, we present the case of Chinese herbal medicines as an example, as they have been extensively used in the global market and increasingly studied worldwide. We analyze the potential reasons for problems and propose some ways forward. As in the case of any drug, clinical trials for safety, efficacy, and/or effectiveness are the ultimate demonstration of therapeutic usefulness of herbal products. These will only make scientific sense when the tested herbal products are authentic, standardized, and quality controlled, if good practice guidelines of evidence-based medicine are followed, and if relevant controls and outcome measures are scientifically defined. Herbal products are complex mixtures, and for such complexity, an obvious approach for mechanistic studies is network pharmacology based on omic tools and approaches, which has already begun to revolutionize the study of conventional drugs, emphasizing networks, interactions, and polypharmacological features behind the action of many drugs.
Collapse
Affiliation(s)
- Olavi Pelkonen
- Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Qihe Xu
- Department of Renal Medicine, King's College London, London, UK
| | - Tai-Ping Fan
- Department of Pharmacology, University of Cambridge, Cambridge, UK
| |
Collapse
|
34
|
Liu P, Yang H, Long F, Hao HP, Xu X, Liu Y, Shi XW, Zhang DD, Zheng HC, Wen QY, Li WW, Ji H, Jiang XJ, Zhang BL, Qi LW, Li P. Bioactive equivalence of combinatorial components identified in screening of an herbal medicine. Pharm Res 2014; 31:1788-800. [PMID: 24549817 PMCID: PMC4062815 DOI: 10.1007/s11095-013-1283-1] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Accepted: 12/31/2013] [Indexed: 11/29/2022]
Abstract
Purpose To identify bioactive equivalent combinatorial components (BECCs) in herbal medicines. The exact composition of effective components in herbal medicines is often elusive due to the lack of adequate screening methodology. Herein, we propose a hypothesis that BECCs accounting for the whole efficacy of original herbal medicines could be discovered from a complex mixture of constituents. Methods We developed a bioactive equivalence oriented feedback screening method and applied it to discover the BECCs from an herbal preparation Cardiotonic Pill (CP). The operations include chemical profiling of CP, followed by an iterative loop of determining, collecting and evaluating candidate BECCs. Results A combination of 18 compounds was identified as BECCs from CP, which accounts for 15.0% (w/w) of original CP. We have demonstrated that the BECCs were as effective as CP in cell models and in a rat model of myocardial infarction. Conclusions This work answers the key question of which are real bioactive components for CP that have been used in clinic for many years, and provides a promising approach for discovering BECCs from herbal medicines. More importantly, the BECCs could be extended to improve quality control of herbal products and inspire an herbal medicines based discovery of combinatorial therapeutics. Electronic supplementary material The online version of this article (doi:10.1007/s11095-013-1283-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Peng Liu
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Pan S, Neeraj A, Srivastava KS, Kishore P, Danquah MK, Sarethy IP. A Proposal for a Quality System for Herbal Products. J Pharm Sci 2013; 102:4230-41. [DOI: 10.1002/jps.23732] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2013] [Revised: 08/19/2013] [Accepted: 09/03/2013] [Indexed: 11/06/2022]
|
36
|
Inacio JDF, Canto-Cavalheiro MM, Almeida-Amaral EE. In vitro and in vivo effects of (-)-epigallocatechin 3-O-gallate on Leishmania amazonensis. JOURNAL OF NATURAL PRODUCTS 2013; 76:1993-1996. [PMID: 24106750 DOI: 10.1021/np400624d] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
(-)-Epigallocatechin 3-O-gallate (1), the most abundant flavanol in green tea, has been reported to have antiproliferative effects on Trypanosoma cruzi. The present study reports the effects in vitro and in vivo of 1 on Leishmania amazonensis. L. amazonensis-infected macrophages treated with 1 exhibited a significant reduction of the infection index in a dose-dependent manner, with an IC50 value of 1.6 μM. Oral administration of 1 on L. amazonensis-infected BALB/c mice (30 mg/kg/day) resulted in a decrease in the lesion size and parasite burden, without altering serological markers of toxicity. These data demonstrate the in vitro and in vivo leishmanicidal effects of compound 1.
Collapse
Affiliation(s)
- Job D F Inacio
- Laboratório de Bioquímica de Tripanosomatideos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz , Pavilhão Leônidas Deane, Manguinhos, 21045-900, Rio de Janeiro, Brazil
| | | | | |
Collapse
|
37
|
Sharma V, Sarkar IN. Leveraging biodiversity knowledge for potential phyto-therapeutic applications. J Am Med Inform Assoc 2013; 20:668-79. [PMID: 23518859 PMCID: PMC3721164 DOI: 10.1136/amiajnl-2012-001445] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2012] [Revised: 02/02/2013] [Accepted: 03/02/2013] [Indexed: 12/31/2022] Open
Abstract
OBJECTIVE To identify and highlight the feasibility, challenges, and advantages of providing a cross-domain pipeline that can link relevant biodiversity information for phyto-therapeutic assessment. MATERIALS AND METHODS A public repository of clinical trials information (ClinicalTrials.gov) was explored to determine the state of plant-based interventions under investigation. RESULTS The results showed that ≈ 15% of drug interventions in ClinicalTrials.gov were potentially plant related, with about 60% of them clustered within 10 taxonomic families. Further analysis of these plant-based interventions identified ≈ 3.7% of associated plant species as endangered as determined from the International Union for the Conservation of Nature Red List. DISCUSSION The diversity of the plant kingdom has provided human civilization with life-sustaining food and medicine for centuries. There has been renewed interest in the investigation of botanicals as sources of new drugs, building on traditional knowledge about plant-based medicines. However, data about the plant-based biodiversity potential for therapeutics (eg, based on genetic or chemical information) are generally scattered across a range of sources and isolated from contemporary pharmacological resources. This study explored the potential to bridge biodiversity and biomedical knowledge sources. CONCLUSIONS The findings from this feasibility study suggest that there is an opportunity for developing plant-based drugs and further highlight taxonomic relationships between plants that may be rich sources for bioprospecting.
Collapse
Affiliation(s)
- Vivekanand Sharma
- Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA
| | - Indra Neil Sarkar
- Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA
- Biomedical Informatics Unit, Center for Clinical and Translational Science, University of Vermont, Burlington, Vermont, USA
- Department of Computer Science, University of Vermont, Burlington, Vermont, USA
| |
Collapse
|
38
|
Xu Q, Bauer R, Hendry BM, Fan TP, Zhao Z, Duez P, Simmonds MSJ, Witt CM, Lu A, Robinson N, Guo DA, Hylands PJ. The quest for modernisation of traditional Chinese medicine. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE 2013; 13:132. [PMID: 23763836 PMCID: PMC3689083 DOI: 10.1186/1472-6882-13-132] [Citation(s) in RCA: 110] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/17/2013] [Accepted: 05/28/2013] [Indexed: 01/17/2023]
Abstract
Traditional Chinese medicine (TCM) is an integral part of mainstream medicine in China. Due to its worldwide use, potential impact on healthcare and opportunities for new drug development, TCM is also of great international interest. Recently, a new era for modernisation of TCM was launched with the successful completion of the Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era (GP-TCM) project, the European Union's Seventh Framework Programme (FP7) coordination action on TCM research. This 3.5-year project that involved inputs from over 200 scientists resulted in the production of 20 editorials and in-depth reviews on different aspects of TCM that were published in a special issue of Journal of Ethnopharmacology (2012; volume 140, issue 3). In this narrative review, we aim to summarise the findings of the FP7 GP-TCM project and highlight the relevance of TCM to modern medicine within a historical and international context. Advances in TCM research since the 1950s can be characterised into three phases: Phase I (1950s-1970s) was fundamental for developing TCM higher education, research and hospital networks in China; Phase II (1980s-2000s) was critical for developing legal, economic and scientific foundations and international networks for TCM; and Phase III (2011 onwards) is concentrating on consolidating the scientific basis and clinical practice of TCM through interdisciplinary, interregional and intersectoral collaborations. Taking into account the quality and safety requirements newly imposed by a globalised market, we especially highlight the scientific evidence behind TCM, update the most important milestones and pitfalls, and propose integrity, integration and innovation as key principles for further modernisation of TCM. These principles will serve as foundations for further research and development of TCM, and for its future integration into tomorrow's medicine.
Collapse
Affiliation(s)
- Qihe Xu
- King's College London, Department of Renal Medicine, London, UK
| | - Rudolf Bauer
- Institute of Pharmaceutical Sciences, Department of Pharmacognosy, Karl-Franzens-University Graz, Graz, Austria
| | - Bruce M Hendry
- King's College London, Department of Renal Medicine, London, UK
| | - Tai-Ping Fan
- Department of Pharmacology, University of Cambridge, Cambridge, UK
| | - Zhongzhen Zhao
- School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
| | - Pierre Duez
- Laboratory of Pharmacognosy, Bromatology and Human Nutrition, Université Libre de Bruxelles, Brussels, Belgium
| | | | - Claudia M Witt
- Institute for Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin, Berlin, Germany
| | - Aiping Lu
- School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
| | - Nicola Robinson
- Allied Health Sciences, Faculty of Health and Social Care, London South Bank University, London, UK
| | - De-an Guo
- Shanghai Research Centre for TCM Modernisation, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Peter J Hylands
- King's College London, Institute of Pharmaceutical Science, London, UK
| |
Collapse
|
39
|
Jiang B, Kronenberg F, Balick MJ, Kennelly EJ. Stability of black cohosh triterpene glycosides and polyphenols: potential clinical relevance. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2013; 20:564-569. [PMID: 23415548 DOI: 10.1016/j.phymed.2012.12.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/10/2012] [Revised: 11/09/2012] [Accepted: 12/24/2012] [Indexed: 06/01/2023]
Abstract
Concurrent to a clinical trial of black cohosh for menopausal hot flashes, the long-term stability of the black cohosh, over the duration of the clinical trial, was examined. Analytical results showed that the major constituents, both triterpene glycosides and polyphenols, were stable over the 3-year period of testing. These results indicate that a black cohosh product stored for several years in a controlled environment does not undergo significant changes in its major constituents. These results have implications not only for clinical research in natural products, but for basic science, as well as the dietary supplements industry.
Collapse
Affiliation(s)
- Bei Jiang
- The Richard and Hinda Rosenthal Center for Complementary & Alternative Medicine, College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA
| | | | | | | |
Collapse
|
40
|
Research and development for botanical products in medicinals and food supplements market. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2013; 2013:649720. [PMID: 23606886 PMCID: PMC3625613 DOI: 10.1155/2013/649720] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/31/2013] [Accepted: 03/05/2013] [Indexed: 11/18/2022]
Abstract
Botanical products sold in the health area are generally intended as drugs, medicinal products, food supplements or substances for therapeutic use. Use of botanicals for improving or to care human health has evolved independently in different countries worldwide. Regulatory issues regarding botanical products designed for the food supplements or medicinal market and their influence on research and development are discussed. European Union (EU) and United States (US) policies regulating these products are focused with comments on the legislations delivered during the last ten years and differences existing in rules between these countries are emphasized. Research and development on botanical products nowdays strongly influenced by the product destination in the market. Addressed and differentiated research for either food supplements or medicinal markets is necessary to purchase data really useful for assessment of safe and effective use for both the categories. The main objective is to catalyze interest of academic and companies' researchers on crucial aspects to be taken into account in the research for the development of botanical products.
Collapse
|
41
|
Leung PC, Cheng KF, Chan YH. An innovative herbal product for the prevention of osteoporosis. Chin J Integr Med 2013; 17:744-9. [DOI: 10.1007/s11655-011-0876-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2010] [Indexed: 10/15/2022]
|
42
|
Agarwal R. US regulatory approaches to chemistry, manufacturing, and controls for botanical drug products. J Transl Med 2012. [PMCID: PMC3480022 DOI: 10.1186/1479-5876-10-s2-a40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- Rajiv Agarwal
- Office of New Drug Quality Assessment, Office of Pharmaceutical Science, US Food and Drug Administration, 10903 New Hampshire AvenueSilver Spring, MD 20903, USA
| |
Collapse
|
43
|
|
44
|
Chen LW, Horng LY, Wu CL, Sung HC, Wu RT. Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease. Neuropharmacology 2012; 63:719-32. [DOI: 10.1016/j.neuropharm.2012.05.019] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2012] [Revised: 04/14/2012] [Accepted: 05/16/2012] [Indexed: 11/26/2022]
|
45
|
Won CS, Oberlies NH, Paine MF. Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther 2012; 136:186-201. [PMID: 22884524 DOI: 10.1016/j.pharmthera.2012.08.001] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2012] [Accepted: 07/23/2012] [Indexed: 12/21/2022]
Abstract
Food-drug interaction studies are critical to evaluate appropriate dosing, timing, and formulation of new drug candidates. These interactions often reflect prandial-associated changes in the extent and/or rate of systemic drug exposure. Physiologic and physicochemical mechanisms underlying food effects on drug disposition are well-characterized. However, biochemical mechanisms involving drug metabolizing enzymes and transport proteins remain underexplored. Several plant-derived beverages have been shown to modulate enzymes and transporters in the intestine, leading to altered pharmacokinetic (PK) and potentially negative pharmacodynamic (PD) outcomes. Commonly consumed fruit juices, teas, and alcoholic drinks contain phytochemicals that inhibit intestinal cytochrome P450 and phase II conjugation enzymes, as well as uptake and efflux transport proteins. Whereas myriad phytochemicals have been shown to inhibit these processes in vitro, translation to the clinic has been deemed insignificant or undetermined. An overlooked prerequisite for elucidating food effects on drug PK is thorough knowledge of causative bioactive ingredients. Substantial variability in bioactive ingredient composition and activity of a given dietary substance poses a challenge in conducting robust food-drug interaction studies. This confounding factor can be addressed by identifying and characterizing specific components, which could be used as marker compounds to improve clinical trial design and quantitatively predict food effects. Interpretation and integration of data from in vitro, in vivo, and in silico studies require collaborative expertise from multiple disciplines, from botany to clinical pharmacology (i.e., plant to patient). Development of more systematic methods and guidelines is needed to address the general lack of information on examining drug-dietary substance interactions prospectively.
Collapse
Affiliation(s)
- Christina S Won
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7569, USA
| | | | | |
Collapse
|
46
|
Wen CC, Chen HM, Yang NS. Developing Phytocompounds from Medicinal Plants as Immunomodulators. ADVANCES IN BOTANICAL RESEARCH 2012; 62:197-272. [PMID: 32300254 PMCID: PMC7150268 DOI: 10.1016/b978-0-12-394591-4.00004-0] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Imbalance or malfunction of the immune systems is associated with a range of chronic diseases including autoimmune diseases, allergies, cancers and others. Various innate and adaptive immune cells that are integrated in this complex networking system may represent promising targets for developing immunotherapeutics for treating specific immune diseases. A spectrum of phytochemicals have been isolated, characterized and modified for development and use as prevention or treatment of human diseases. Many cytotoxic drugs and antibiotics have been developed from phytocompounds, but the application of traditional or new medicinal plants for use as immunomodulators in treating immune diseases is still relatively limited. In this review, a selected group of medicinal herbs, their derived crude or fractionated phytoextracts and the specific phytochemicals/phytocompounds isolated from them, as well as categorized phytocompound groups with specific chemical structures are discussed in terms of their immunomodulatory bioactivities. We also assess their potential for future development as immunomodulatory or inflammation-regulatory therapeutics or agents. New experimental approaches for evaluating the immunomodulatory activities of candidate phytomedicines are also discussed.
Collapse
Affiliation(s)
- Chih-Chun Wen
- Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan
| | - Hui-Ming Chen
- Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan
- Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan
| | - Ning-Sun Yang
- Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan
| |
Collapse
|
47
|
Ferulic acid, a phenolic phytochemical, inhibits UVB-induced matrix metalloproteinases in mouse skin via posttranslational mechanisms. J Nutr Biochem 2012; 23:443-51. [DOI: 10.1016/j.jnutbio.2011.01.009] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2010] [Revised: 01/20/2011] [Accepted: 01/27/2011] [Indexed: 11/15/2022]
|
48
|
Fimognari C, Ferruzzi L, Turrini E, Carulli G, Lenzi M, Hrelia P, Cantelli-Forti G. Metabolic and toxicological considerations of botanicals in anticancer therapy. Expert Opin Drug Metab Toxicol 2012; 8:819-32. [PMID: 22540949 DOI: 10.1517/17425255.2012.685717] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Cancer is a complex disease, characterized by redundant aberrant signaling pathways as a result of genetic perturbations at different levels. Botanicals consist of a complex mixture of constituents and exhibit pharmacological effects by the interaction of many phytochemicals. The multitarget nature of botanicals could, therefore, be a relevant strategy to address the biological complexity that characterizes tumors. AREAS COVERED This article reviews the current status of botanicals in the oncological field and the challenges associated with their complex nature. EXPERT OPINION Botanicals are an important new pharmacological strategy, which are potentially exploitable in the oncological area but are characterized by a number of problems still unresolved. Content variation of products is one of the primary problems with botanicals and, consequently, there is a concern about the therapeutic consistency in marketed batches. Furthermore, metabolic interactions with antineoplastic drugs and the genotoxic potential of botanicals need to be properly addressed throughout the various phases of botanical drug development. These issues not only pose a serious problem to the approvability of those botanical products as new drugs but also present as a limitation to their post-approval clinical use.
Collapse
Affiliation(s)
- Carmela Fimognari
- Alma Mater Studiorum-University of Bologna, Department of Pharmacology, Via Irnerio 48, 40126 Bologna, Italy.
| | | | | | | | | | | | | |
Collapse
|
49
|
Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, Dou JH, Makarov VG, Pozharitskaya ON, Shikov AN, Kim YS, Huang YT, Chang YS, Jia W, Dias A, Wong VCW, Chan K. Future development of global regulations of Chinese herbal products. JOURNAL OF ETHNOPHARMACOLOGY 2012; 140:568-586. [PMID: 22373513 DOI: 10.1016/j.jep.2012.02.029] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2011] [Revised: 02/10/2012] [Accepted: 02/10/2012] [Indexed: 05/31/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE GP-TCM is the first EU-funded Coordination Action consortium dedicated to traditional Chinese medicine (TCM) research. One of the key deliverables of the Work Package 7 in GP-TCM was to investigate information of the existing requirements for registration of TCM products listed by global regulatory bodies. The paper aims to collate data and draw comparison of these regulations. Case studies are also presented to illustrate the problems involved in registering TCM products in different regions worldwide. MATERIALS AND METHODS A collaborative network task force was established during the early stage of the GP-TCM project and operated through exchanges, teleconferences and focused discussions at annual meetings. The task force involved coordinators, academics who are actively involved with R&D of Chinese herbal medicines, experts on monographic standards of Chinese materia medica, representatives from regulatory agencies, experts from industries in marketing Chinese medicines/herbal medicines and natural products. The co-ordinators took turns to chair teleconferences, led discussions on specific issues at AGM discussion sessions, at joint workshops with other work-packages such as WP1 (quality issues), WP3 (toxicology issues) and WP6 (clinical trial issues). Collectively the authors were responsible for collating discussion outcomes and updating written information. RESULTS A global overview of regulations on herbal registration has been compiled during the three years of the consortium. The regulatory requirements for registration of herbal products in the EU and China were compared, and this is extended to other regions/countries: Africa, Australia, Brazil, Canada, Japan, Russia, South Korea, Taiwan, and the United States. A wide variation of the regulations for the categories of herbal products exists: food (functional food, novel foods, dietary food for special medical purpose, foods for particular nutritional use, food supplement); cosmetic, traditional herbal medicine products; herbal medicines for human use and veterinary use. CONCLUSION The regulatory issues for registration of herbal products are complicated among the countries and regions worldwide. The information summarised in the text is for reference only. Some regulations which are presented in this review are still in legislation process and may change in due course. Before taking any regulatory action, readers are advised to consult current official legislation and guidance and/or to seek appropriate professional advice. The lessons learnt from global regulation of TCM will provide valuable insights for regulation of other traditional medicine such as Ayurveda and Unani medicine, as well as other forms of indigenous medicine. The WHO is well placed to co-ordinate a consultation process with the aim of putting forward suggestions for harmonisation to key regulatory agencies.
Collapse
Affiliation(s)
- Tai-Ping Fan
- Department of Pharmacology, University of Cambridge, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Liu SH, Cheng YC. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. JOURNAL OF ETHNOPHARMACOLOGY 2012; 140:614-623. [PMID: 22326673 DOI: 10.1016/j.jep.2012.01.047] [Citation(s) in RCA: 103] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2011] [Revised: 01/24/2012] [Accepted: 01/25/2012] [Indexed: 05/31/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE PHY906, is a decoction of a mixture of the four herbs Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall, and Ziziphus jujuba Mill. A combination of these four herbs has been in continuous use in traditional Chinese medicine for over 1800 years for treating a variety of gastrointestinal distress such as diarrhea, cramps, nausea, vomiting etc. AIM OF THE STUDY Preclinical and clinical studies to find PHY906 enhances the therapeutic indices of a broad spectrum of anticancer agents. MATERIALS AND METHODS Using various mouse tumor xenograft and allograft models, PHY906 has been shown to enhance the chemotherapeutic efficacy of a variety of anticancer agents in various cancers. The PHY906 clinical program consists of five trials in three different types of cancers in both the United States and Taiwan. To date, approximately 150 subjects have received PHY906 in combination with chemotherapy in these five clinical studies. RESULTS Preclinical studies have shown that PHY906 enhances the therapeutic indices of a broad spectrum of anticancer agents. These findings have been examined in clinical studies for colorectal, liver, and pancreatic cancers when PHY906 is used as an adjuvant to chemotherapy and the results were promising; i.e. PHY906 could reduce chemotherapy-induced toxicities and/or increase chemotherapeutic efficacy. Furthermore, PHY906 did not affect the pharmacokinetics of the chemotherapeutic agents used. Some information has been obtained regarding the mechanism of action of PHY906 in preclinical studies. A comprehensive platform, PhytomicsQC that integrates chemical and biological fingerprints together with a novel biostatistical methodology has been developed to assess the quality of different batches of PHY906. CONCLUSIONS Over a ten-year period, the multiplex technology "PhytomicsQC" has been used to show batch-to-batch consistency of PHY906 production. Advanced clinical trials are ongoing to demonstrate the effectiveness of PHY906 as adjuvant therapy for cancer patients undergoing chemotherapy.
Collapse
|